Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
20,317 results
- Volatilome and Single-Lead Electrocardiogram Optimize Ischemic Heart Disease Diagnosis Using Machine Learning Models: Complete Statistical AnalysisIndependent statistical analysis of Volatilome and Single-Lead Electrocardiogram Optimize Ischemic Heart Disease Diagnosis Using Machine Learning Models: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study: Complete Statistical AnalysisIndependent statistical analysis of Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study: primary endpoint results, effect estimate with…
- VOLVERIndependent statistical analysis of Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- VOR-IISRIndependent statistical analysis of Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02969876).
- Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00958074).
- Vorinostat in Treating Patients With Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat in Treating Patients With Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00305773).
- Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00330161).
- Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00238303).
- Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM): Complete Statistical AnalysisIndependent statistical analysis of Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma: primary endpoint results, effect estimate with…
- Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma: primary endpoint results, effect…
- Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction: Complete Statistical AnalysisIndependent statistical analysis of Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy: Complete Statistical AnalysisIndependent statistical analysis of Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- VOTIVEIndependent statistical analysis of Virginia Opioid Overdose Treatment InitiatVE: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03818399).
- VOYAGEIndependent statistical analysis of Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- VOYAGERIndependent statistical analysis of A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- VOYAGER PADIndependent statistical analysis of Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower…
- VPAIndependent statistical analysis of Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval Study: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- VPCIndependent statistical analysis of Co-Design and Pilot Testing of Peer-led Community Outreach to Improve Equity, Veteran-Centeredness and Uptake of Lung Cancer Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- VPCOVIDIndependent statistical analysis of VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04452669).
- VPESIndependent statistical analysis of Vanderbilt Pertussis Exposure Study: PEP in Vaccinated Healthcare Workers Following Pertussis Exposure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- VRIndependent statistical analysis of Immersive Virtual Reality in Stroke Pilot Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04429945).
- VR-DCSIndependent statistical analysis of Virtual Reality & D-cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00632632).
- VR-IOMSIndependent statistical analysis of Virtual Reality-Base Intelligent Orientation and Mobility Specialists Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04639531).
- VR-THEIAIndependent statistical analysis of Impact of Virtual Reality on Pre-procedural anxieTy Prior to Heart cathEterIzAtion - VR-THEIA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- VRC 603Independent statistical analysis of Safety and Tolerability of AAV8 Delivery of a Broadly Neutralizing Antibody in Adults Living With HIV: a Phase 1, Dose-escalation Trial: primary endpoint results, effect estimate with confidence…
- VRC 611Independent statistical analysis of A Phase 1 Trial to Evaluate CAP256V2LS in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04408963).
- VRC 614Independent statistical analysis of Trial to Evaluate L9LS in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05019729).
- VRI01Independent statistical analysis of Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- VRPE ExtensionIndependent statistical analysis of Comparing Virtual Reality Exposure Therapy to Prolonged Exposure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01459705).
- VSLIndependent statistical analysis of Veteran Stress and Learning Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00674570).
- VX-950-C211 – A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection: Complete Statistical AnalysisIndependent statistical analysis of VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection: primary endpoint results,…
- Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan): Complete Statistical AnalysisIndependent statistical analysis of Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02146378).
- VyvanceIndependent statistical analysis of Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01486810).
- Vyxeos for Induction of Low- or Intermediate-risk.: Complete Statistical AnalysisIndependent statistical analysis of Vyxeos for Induction of Low- or Intermediate-risk.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05599360).
- W-SUDs for COVID-19: Complete Statistical AnalysisIndependent statistical analysis of W-SUDs for COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04460027).
- W8Loss2Go: mHealth Weight Management Strategy: Complete Statistical AnalysisIndependent statistical analysis of W8Loss2Go: mHealth Weight Management Strategy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02689154).
- Wait and SeeIndependent statistical analysis of Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Walk Assist Device to Improve Community Ambulation: Complete Statistical AnalysisIndependent statistical analysis of Walk Assist Device to Improve Community Ambulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03222505).
- Walking Aids in the Management of Hip Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of Walking Aids in the Management of Hip Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00506714).
- Walking Aids in the Management of Knee Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of Walking Aids in the Management of Knee Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00223795).
- Walking to School Supports: Complete Statistical AnalysisIndependent statistical analysis of Walking to School Supports: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04089020).
- WalkITIndependent statistical analysis of A Walking Intervention Through Text Messaging: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02053259).
- Warming Blanket Comparison Study: Complete Statistical AnalysisIndependent statistical analysis of Warming Blanket Comparison Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04776954).
- Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup in Patients Suffering a URTI: Complete Statistical AnalysisIndependent statistical analysis of Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup in Patients Suffering a URTI: primary endpoint results, effect…
- WATCHMAN FLX™ CT Study: Complete Statistical AnalysisIndependent statistical analysis of WATCHMAN FLX™ CT Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05324371).
- WATERIndependent statistical analysis of Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02505919).
- WAVEIndependent statistical analysis of Durvalumab Long-Term Safety and Efficacy Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04078152).